|
1
|
Carvalho S, Gonçalves ÓF, Brunoni AR,
Fernandes-Gonçalves A, Fregni F and Leite J: Transcranial direct
current stimulation as an add-on treatment to cognitive-behavior
therapy in first episode drug-naïve major depression patients: The
ESAP study protocol. Front Psychiatry. 11(563058)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cosker E, Moulard M, Schmitt S,
Angioi-Duprez K, Baumann C, Laprévote V, Schwan R and Schwitzer T:
Portable light therapy in the treatment of unipolar non-seasonal
major depressive disorder: Study protocol for the LUMIDEP
randomised controlled trial. BMJ Open. 11(e049331)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan
J, Yu Y, Kou C, Xu X, Lu J, et al: Prevalence of mental disorders
in China: A cross-sectional epidemiological study. Lancet
Psychiatry. 6:211–224. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Doboszewska U, Wlaź P, Nowak G,
Radziwoń-Zaleska M, Cui R and Młyniec K: Zinc in the monoaminergic
theory of depression: Its relationship to neural plasticity. Neural
Plast. 2017(3682752)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
McCall WV, Lisanby SH, Rosenquist PB,
Dooley M, Husain MM, Knapp RG, Petrides G, Rudorfer MV, Young RC,
McClintock SM, et al: Effects of continuation electroconvulsive
therapy on quality of life in elderly depressed patients: A
randomized clinical trial. J Psychiatr Res. 97:65–69.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nikayin S and Sanacora G: Evaluating the
role of ketamine/esketamine in the management of major depressive
disorder with suicide risk. CNS Drugs. 35:1069–1079.
2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Roca M, Del Amo AR, Riera-Serra P,
Pérez-Ara MA, Castro A, Roman Juan J, García-Toro M, García-Pazo P
and Gili M: Suicidal risk and executive functions in major
depressive disorder: A study protocol. BMC Psychiatry.
19(253)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nowak W, Grendas LN, Sanmarco LM, Estecho
IG, Arena ÁR, Eberhardt N, Rodante DE, Aoki MP, Daray FM, Carrera
Silva EA and Errasti AE: Pro-inflammatory monocyte profile in
patients with major depressive disorder and suicide behaviour and
how ketamine induces anti-inflammatory M2 macrophages by NMDAR and
mTOR. EBioMedicine. 50:290–305. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pacheco DDF, Romero TRL and Duarte IDG:
Ketamine induces central antinociception mediated by endogenous
cannabinoids and activation of CB1 receptors. Neurosci Lett.
699:140–144. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Khakpai F, Ebrahimi-Ghiri M, Alijanpour S
and Zarrindast MR: Ketamine-induced antidepressant like effects in
mice: A possible involvement of cannabinoid system. Biomed
Pharmacother. 112(108717)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pitsillou E, Bresnehan SM, Kagarakis EA,
Wijoyo SJ, Liang J, Hung A and Karagiannis TC: The cellular and
molecular basis of major depressive disorder: Towards a unified
model for understanding clinical depression. Mol Biol Rep.
47:753–770. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lindqvist D, Dhabhar FS, James SJ, Hough
CM, Jain FA, Bersani FS, Reus VI, Verhoeven JE, Epel ES, Mahan L,
et al: Oxidative stress, inflammation and treatment response in
major depression. Psychoneuroendocrinology. 76:197–205.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chang CC, Jou SH, Lin TT, Lai TJ and Liu
CS: Mitochondria DNA change and oxidative damage in clinically
stable patients with major depressive disorder. PLoS One.
10(e0125855)2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Czarny P, Wigner P, Galecki P and
Sliwinski T: The interplay between inflammation, oxidative stress,
DNA damage, DNA repair and mitochondrial dysfunction in depression.
Prog Neuropsychopharmacol Biol Psychiatry. 80:309–321.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sharma S and Akundi RS: Mitochondria: A
connecting link in the major depressive disorder jigsaw. Curr
Neuropharmacol. 17:550–562. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Maher P, van Leyen K, Dey PN, Honrath B,
Dolga A and Methner A: The role of Ca2+ in cell death caused by
oxidative glutamate toxicity and ferroptosis. Cell Calcium.
70:47–55. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xing Y, Zhang M, Li WB, Dong F and Zhang
F: Mechanisms involved in the neuroprotection of electroacupuncture
therapy for ischemic stroke. Front Neurosci. 12(929)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang S, Hu B, Wang Z, Zhang C, Jiao H, Mao
Z, Wei L, Jia J and Zhao J: Cannabinoid CB1 receptor agonist ACEA
alleviates brain ischemia/reperfusion injury via CB1-Drp1 pathway.
Cell Death Discov. 6(102)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jia J, Zhang L, Shi X, Wu M, Zhou X, Liu X
and Huo T: SOD2 mediates amifostine-induced protection against
glutamate in PC12 cells. Oxid Med Cell Longev.
2016(4202437)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang Q, Hong S, Cao J, Zhou Y, Xu X, Ai M
and Kuang L: Hippocampal subfield volumes in major depressive
disorder adolescents with a history of suicide attempt. Biomed Res
Int. 2021(5524846)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cipriani A, Furukawa TA, Salanti G,
Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH,
Higgins JPT, et al: Comparative efficacy and acceptability of 21
antidepressant drugs for the acute treatment of adults with major
depressive disorder: A systematic review and network meta-analysis.
Focus (Am Psychiatr Publ). 16:420–429. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xu W, Li H, Wang L, Zhang J, Liu C, Wan X,
Liu X, Hu Y, Fang Q, Xiao Y, et al: Endocannabinoid signaling
regulates the reinforcing and psychostimulant effects of ketamine
in mice. Nat Commun. 11(5962)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen DJ, Gao M, Gao FF, Su QX and Wu J:
Brain cannabinoid receptor 2: Expression, function and modulation.
Acta Pharmacol Sin. 38:312–316. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vaváková M, Ďuračková Z and Trebatická J:
Markers of oxidative stress and neuroprogression in depression
disorder. Oxid Med Cell Longev. 2015(898393)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Giménez-Palomo A, Dodd S, Anmella G,
Carvalho AF, Scaini G, Quevedo J, Pacchiarotti I, Vieta E and Berk
M: The role of mitochondria in mood disorders: From physiology to
pathophysiology and to treatment. Front Psychiatry.
12(546801)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lener MS, Niciu MJ, Ballard ED, Park M,
Park LT, Nugent AC and Zarate CA Jr: Glutamate and
gamma-aminobutyric acid systems in the pathophysiology of major
depression and antidepressant response to ketamine. Biol
Psychiatry. 81:886–897. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zelko IN, Mariani TJ and Folz RJ:
Superoxide dismutase multigene family: A comparison of the CuZn-SOD
(SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures,
evolution, and expression. Free Radic Biol Med. 33:337–349.
2002.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ma L, Jia J, Niu W, Jiang T, Zhai Q, Yang
L, Bai F, Wang Q and Xiong L: Mitochondrial CB1 receptor is
involved in ACEA-induced protective effects on neurons and
mitochondrial functions. Sci Rep. 5(12440)2015.PubMed/NCBI View Article : Google Scholar
|
